Viatris (NASDAQ:VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker announced positive outcomes to several Phase 3 trials alongside better-than-expected ...

This settlement is in no way an admission of wrongdoing or liability. Viatris OUS Logo (PRNewsfoto/Viatris Inc.) The Company will also continue its longstanding role of working to identify ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

This marks a significant milestone in the company's investment in South Africa, while underscoring Viatris’ commitment to utilising global, regional, and local supply chains to ensure that ...

The Nasdaq imagery, which uses the colors in Viatris’ logo, starts with the message “everywhere health matters” on a plain background. A series of still images shows what that means in practice.

Viatris sought approval of Actelion blood-pressure drug Veletri Fed Cir says lower court may have misinterpreted J&J patents The U.S. Court of Appeals for the Federal Circuit said that a West ...

Viatris colleagues are passionate about our mission to empower people worldwide to live healthier at every stage of life. Together, we are building a performance driven, highly engaging and inclusive ...

Viatris is trying to get its two generic versions of semaglutide approved for sale. Novo Nordisk is suing Viatris to prevent the approval from happening. Even if Viatris succeeds, it might ...

Viatris Inc (Symbol: VTRS) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash ...